Patient reported outcomes in adults with severe eosinophilic asthma on benralizumab. - POWER

Study identifier:D3250R00041

ClinicalTrials.gov identifier:NCT03833141

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Patient Outcomes Real World Evidence Registry (POWER): patient reported outcomes in a cohort of Canadian adults with severe eosinophilic asthma on benralizumab.

Medical condition

Severe Eosinophilic Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

170

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 12 Nov 2018
Primary Completion Date: 28 May 2024
Study Completion Date: 28 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria